MSMathias Spitaleri

Mathias Spitaleri

*This is an algorithmically generated author record based on publicly available information.

Mathias Spitaleri has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    THE IMPACT OF POLYCYSTIC OVARY SYNDROME (PCOS) ON THE MENTAL HEALTH OF PATIENTS – A CROSS-SECTIONAL STUDY WITH EXTENDED CLINICAL AND PUBLIC HEALTH IMPLICATIONS

    by Julia Konat, Jan Noskowicz, Jan Urban, Wiktor Doroszuk, Dawid Sewruk, Katarzyna Sikora, Mathias Spitaleri, Arleta Gieniec, Filip Kieloch, Agnieszka Fitas

    Background: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting up to 10% of reproductive-aged women. Beyond reproductive symptoms, PCOS is increasingly associated with mental health challenges, including depression, anxiety, and stress, often overlooked in routine care. Aim: This study assessed the prevalence and severity of psychological symptoms in women with PCOS and identified clinical and behavioral predictors of poor outcomes, with emphasis on modifiable lifestyle factors. Methods: A cross-sectional study was conducted among 200 women aged 18–40 diagnosed with PCOS by Rotterdam criteria. Participants completed the Depression, Anxiety and Stress Scale-21 (DASS-21) and a survey on sleep, physical activity, nutrition, and social support. Clinical indicators included BMI, menstrual regularity, hirsutism, and acne. Pearson correlations and regression models were used to analyze associations. Results: Moderate to severe depression affected 62% of participants, elevated anxiety 54%, and high stress 38%. Higher BMI, irregular cycles, and hirsutism were strongly correlated with worse psychological scores. Protective factors included regular physical activity, sufficient sleep, and positive body image. Regression analyses confirmed both clinical and behavioral predictors were significant (p < 0.05). Conclusions: Women with PCOS experience a substantial psychological burden. Routine care should integrate mental health screening and multidisciplinary management. Lifestyle interventions focusing on exercise, sleep, and body image may significantly improve emotional well-being and overall quality of life.

  • Open Access

    KETAMINE AS AN OPTIONAL TREATMENT IN CHRONIC PAIN - A REVIEW

    by Mathias Spitaleri, Karol Kanon, Filip Kieloch, Julia Głowacka, Agnieszka Fitas, Wojciech Gąska, Karolina Dębek-Kalinowska, Oskar Sienkiel, Wiktor Gąska, Dawid Sewruk

    Chronic pain is a pervasive and debilitating condition that affects millions of individuals worldwide. Traditional methods of pain management, including the use of opioids, often fall short in providing adequate relief and come with significant risks, such as dependency and tolerance. As a result, there has been growing interest in exploring alternative treatments, with ketamine emerging as a promising option. Ketamine, a dissociative anesthetic, has shown potential in alleviating various types of chronic pain, including neuropathic pain, cancer-related pain, and pain associated with complex regional pain syndrome (CRPS). Aim of study: This review aims to examine the current evidence on the efficacy of ketamine in chronic pain management, exploring its mechanisms of action, clinical applications, safety profile, and potential limitations. Methods and materials: PubMed and Scopus databases were used to search for topic treated articles.

  • Open Access

    COMPREHENSIVE REVIEW OF TREATMENT OPTIONS FOR ERECTILE DYSFUNCTION: MODERN AND TRADITIONAL METHODS

    by Oskar Sienkiel, Agnieszka Fitas, Wojciech Gąska, Julia Głowacka, Mathias Spitaleri, Filip Kieloch, Dawid Sewruk, Wiktor Gąska, Karol Kanon, Karolina Dębek-Kalinowska

    Introduction: Erectile dysfunction (ED), or impotence, is a condition where a man can't get or keep an erection firm enough for satisfying sexual intercourse. It affects men of all ages and is caused by a variety of physical, psychological, or social factors. The number of ED cases is growing annually, and treatment costs are rising steadily. This combination of increasing prevalence and rising expenses highlights the need for a highly optimized treatment method. Efforts should focus on finding a solution that is as effective as possible while also being cost-efficient. The goal is to provide accessible, high-quality care without the financial burden, ensuring that men who suffer from this condition can find relief and improve their quality of life. The search for such a method is crucial given the growing impact of ED on men worldwide. Aim: The aim of this study was to review literature studies on ED and methods for treating this condition. Method: Data for the article were retrieved by using Pub Med setting the time descriptor to 2020-2025. Conclusions: Despite the availability of many effective treatments for erectile dysfunction (ED), it can still be a challenging condition due to the variety of underlying causes. Therefore, an individualized approach and thorough diagnostics are essential. Regenerative therapies and shockwave therapy, although still experimental, offer new therapeutic opportunities. In the future, it will be important to conduct randomized studies with long-term follow-up to assess the effectiveness and safety of these new methods.

  • Open Access

    CEREBELLAR LIPONEUROCYTOMA IN THE LAST DECADE: A COMPREHENSIVE CASE REVIEW

    by Oskar Sienkiel, Julia Czerwik, Marcin Narloch, Jan Tomczyk, Mateusz Jasiński, Aleksandra Żywicka, Michał Szalach, Kamila Mozga, Mathias Spitaleri, Dawid Sewruk, et al.

    Introduction. Tumors of the central nervous system (CNS) are relatively uncommon when compared with neoplasms arising in other organs and tissues of the human body. Among these rare entities, cerebellar liponeurocytoma represents one of the least frequently encountered tumor types. This neoplasm was originally described in 1978 by Bechtel and colleagues, who referred to it as a “mixed mesenchymal and neuroectodermal tumor” due to its unusual histological characteristics combining neuronal and lipomatous differentiation. Since that time, only a limited number of cases have been reported in the literature, underlining its exceptional rarity. In subsequent decades, advances in neuropathology and molecular diagnostics have allowed for more precise recognition of this lesion as a distinct clinicopathological entity. Within the World Health Organization (WHO) classification of tumors of the central nervous system published in 2016, cerebellar liponeurocytoma was formally designated as a grade II tumor. This reflects its generally indolent biological behavior but also acknowledges the significant potential for local recurrence following treatment. Aim of the Study. The aim of the study was to collect data about symptoms and immunoreactivity of cerebellar liponeurocytoma from published cases between 2014 and 2024. Materials and Methods. PubMed and Scopus databases were used to search for cerebellar liponeurocytoma cases. Result. Analyzing data from 32 cases of cerebellar liponeurocytoma, 11 men (34.4%) and 21 women (65.6%) were affected. The mean age was 42.9 ± 18.17 years. The youngest person was 6 years old and the oldest was 77. Two cases concerned patients under 18 years old. The most common tumor location was the posterior fossa (25/32 cases, 78.12%), followed by the ventricle area (4 cases, 12.5%) and the frontal lobe (1 case). The most common symptoms were headache (26/32, 81.25%), vomiting and nausea (15/32, 46.9%), gait disturbance (14/32, 44%), ataxia (3/32, 9.4%), paresthesia (3/32, 9.4%), and urge incontinence (1 case). Conclusion. Cerebellar liponeurocytoma is a rare but distinctive tumor of the central nervous system. The usual symptoms arise from the tumor's typical location in the cerebellum. Its clinical course, with atypical features, may pose significant management challenges. Further research into the tumor's molecular and genetic characteristics is needed to provide insights into optimizing management strategies and improving patient outcomes.

  • Open Access

    THE ROLE OF LIFESTYLE MEDICINE IN TYPE 2 DIABETES: A COMPREHENSIVE REVIEW

    by Wojciech Gąska, Julia Głowacka, Mathias Spitaleri, Filip Kieloch, Dawid Sewruk, Oskar Sienkiel, Agnieszka Fitas, Wiktor Gąska, Karol Kanon, Karolina Dębek-Kalinowska

    Background: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder strongly linked to modifiable lifestyle factors. Lifestyle medicine provides a multidomain, evidence-based framework for prevention and management of T2DM and its complications. Objective: This narrative review synthesizes evidence on six lifestyle medicine domains—diet, physical activity, sleep, smoking cessation, stress management, and social support—in improving glycemic control, insulin sensitivity, and overall health in adults with T2DM. Methods: A PubMed search was conducted using keywords including “type 2 diabetes,” “lifestyle medicine,” “diet,” “physical activity,” “sleep,” “smoking cessation,” “stress,” “mindfulness,” and “social support.” Peer-reviewed English-language studies were prioritized, emphasizing systematic reviews, meta-analyses, randomized controlled trials, and large cohort studies. Relevant guidelines and professional society reports were also reviewed. Results: Carbohydrate-restricted, low-glycemic-index, and Mediterranean diets reduced HbA1c by 0.7–1.8% and fasting glucose by up to 1.3 mmol/L. Aerobic plus resistance training improved HbA1c (~0.7%), HOMA-IR, and VO₂ peak. Optimal sleep (7–8 h) correlated with better glycemic control, while short or long durations worsened HbA1c by 0.2–0.3%. Smoking impaired insulin sensitivity and β-cell function, whereas cessation reduced cardiovascular risk. Stress reduction and mindfulness programs lowered HbA1c by ~0.3% and improved mental health. Social interventions, including structured education and peer support, decreased HbA1c by ~0.25% and reduced isolation-related risks. Conclusion: Lifestyle medicine offers synergistic, non-pharmacological strategies that enhance glycemic control, slow T2DM progression, and improve quality of life. Incorporating these interventions into routine practice is crucial for comprehensive diabetes care.

  • Open Access

    VULVODYNIA AND ITS IMPACT ON WOMEN’S QUALITY OF LIFE

    by Agnieszka Fitas, Filip Kieloch, Dawid Sewruk, Karol Kanon, Julia Głowacka, Mathias Spitaleri, Wiktor Gąska, Karolina Dębek-Kalinowska, Wojciech Gąska, Oskar Sienkiel

    Introduction: Vulvodynia is defined as chronic vulvar pain or discomfort lasting for at least three months without a clear somatic, infectious or neurological cause. Despite growing interest in the field of chronic pain in gynecology, vulvodynia remains poorly recognized and frequently marginalized in clinical practice. Material and methods: This article is based on a review of scientific literature available in databases such as PubMed and Scopus covering publications from 2000 to 2024 on vulvodynia and its impact on women’s quality of life. The analysis includes original studies, systematic reviews and clinical guidelines by the International Pelvic Pain Society (IPPS) and the International Society for the Study of Vulvovaginal Disease (ISSVD). Aim of study: The aim is to present the current state of knowledge on vulvodynia with a focus on its impact on women’s quality of life, including mental health, sexual functioning, social relationships and work activity. Conclusion: Vulvodynia remains a significant and underdiagnosed health problem with serious consequences for women’s quality of life. Increasing awareness and education among healthcare professionals are essential to improve diagnosis and management of vulvodynia. Promoting further research, expanding access to interdisciplinary care and integrating medical, psychological and physiotherapeutic interventions may contribute to more effective treatment, improved functioning of affected women and reduction of the broader socioeconomic burden associated with the disease.

  • Open Access

    EXPLORING THE ROLE OF TELEMEDICINE IN MODERN HEALTHCARE SERVICES: A REVIEW

    by Wiktor Gąska, Agnieszka Fitas, Wojciech Gąska, Julia Głowacka, Mathias Spitaleri, Filip Kieloch, Dawid Sewruk, Oskar Sienkiel, Karol Kanon, Karolina Dębek-Kalinowska

    Objective: Telemedicine, defined as the distribution of health-related services and information via telecommunication technologies, has rapidly evolved from a niche solution into a central component of modern healthcare systems. As healthcare systems around the world contend with the challenges of aging populations, a rise in chronic diseases, and a growing shortage of healthcare professionals, telemedicine could be an effective solution, offering innovative ways to expand access to care, enhance patient outcomes and optimize resource use. The aim of this review is to critically explore and evaluate the role of telemedicine in modern healthcare services, with a specific focus on its applications in managing chronic diseases, acute care, and mental health services. This study seeks to analyze the benefits, challenges, and limitations associated with the widespread adoption of telemedicine. Methods: The article is the result of review of recent scientific literature using PubMed database. Literature was reviewed using keywords. Key findings: In recent years, telemedicine has demonstrated significant benefits in enhancing healthcare delivery, particularly in chronic disease management, acute care, and mental health services. Evidence shows improved patient outcomes, reduced hospitalizations, and greater accessibility for underserved populations. The COVID-19 pandemic accelerated telemedicine adoption, highlighting its value in ensuring continuity of care and fostering technological innovation, such as AI-driven diagnostics and remote monitoring. Despite these advantages, barriers such as the digital divide, regulatory challenges, and limitations in conducting physical examinations persist. Conclusion: Telemedicine has rapidly become an integral component of modern healthcare, offering significant benefits in chronic disease management, acute care, and mental health services. The flexibility and accessibility it provides have proven invaluable, particularly during the COVID-19 pandemic, where it ensured continuity of care while minimizing risks. With continued innovation and thoughtful integration, telemedicine is poised to play a crucial role in the future of healthcare, enhancing patient outcomes and expanding access to essential services, despite its challenges.

  • Open Access

    DUTASTERIDE AS AN EFFECTIVE TREATMENT IN ANDROGENETIC ALOPECIA – A LITERATURE REVIEW

    by Dawid Sewruk, Karol Kanon, Mathias Spitaleri, Wiktor Gąska, Oskar Sienkiel, Filip Kieloch, Agnieszka Fitas, Wojciech Gąska, Karolina Dębek-Kalinowska, Julia Głowacka

    Introduction: Androgenetic alopecia (AGA) is a common hereditary condition characterized by progressive hair loss in both men and women. While not a direct health threat, AGA significantly affects psychological well-being due to the role of hair in self-image and perceived attractiveness. Dutasteride, initially approved for benign prostatic hyperplasia, has demonstrated greater efficacy than finasteride in treating AGA. Its use in mesotherapy may help reduce systemic side effects, although more research is needed to confirm safety and define optimal treatment protocols. Aim of study: To review current evidence on the efficacy and safety of dutasteride in the treatment of AGA and assess its potential as a therapeutic option. Methods and material: A literature search was conducted using PubMed and Scopus to identify relevant studies on the use of dutasteride in AGA. Results: Dutasteride 0.5 mg has shown superior efficacy compared to finasteride 1 mg and placebo in increasing hair count and shaft thickness in men with AGA. As a dual 5α-reductase inhibitor, dutasteride offers broader inhibition than finasteride, which targets only the type 2 isoenzyme. Higher doses, such as 2.5 mg, may yield even greater improvements. Mesotherapy with dutasteride appears to be well tolerated and may reduce systemic exposure, though evidence remains limited, and further studies are required to determine long-term safety and appropriate dosing. Conclusion: Although not officially approved for AGA, dutasteride demonstrates superior clinical efficacy compared to finasteride. Side effects, particularly regarding sexual function, appear similar; however, concerns about long-term risks such as depression and metabolic changes persist. These should be carefully considered in patient consultations. Mesotherapy may offer a safer delivery method, but more robust data are needed to support its widespread use.

  • Open Access

    NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH

    by Bartosz Skorupski, Dominika Nowak, Aleksandra Gradek, Marcin Sawczuk, Jan Noskowicz, Jan Urban, Julia Konat, Patrycja Długosz, Anna Gryc, Mathias Spitaleri

    Introduction and aim of the study: Obesity is a global health issue increasing risks for various diseases and straining healthcare systems. Traditional treatments often prove ineffective, spurring interest in new therapies. GLP-1 receptor agonists have emerged as promising options for treating obesity, gaining attention for their benefits on physical performance and body composition. The aim of this study is to review current knowledge on the mechanisms of action, clinical efficacy, and safety of GLP-1 receptor agonists in obesity treatment, including their implications for public health and potential relevance in physically active populations. Review methods: A literature review was conducted using databases such as PubMed and Google Scholar. The search included keywords like: Obesity; Glucagon-Like Peptide 1; Public Health; Sports Performance; Energy Metabolism. Current state of knowledge: GLP-1 receptor agonists can reduce body weight by 10–21% while decreasing risks of metabolic complications, such as type 2 diabetes and cardiovascular issues. Besides their primary effects, they also regulate appetite, enhance fat oxidation, and improve energy efficiency, attracting interest from physically active individuals looking to optimize body composition. Their action mechanisms include delayed gastric emptying, increased satiety, and enhanced insulin sensitivity. Summary: The use of GLP-1 receptor agonists marks significant progress in obesity treatment with vital public health benefits. However, their off-label use among athletes raises ethical and safety concerns, especially regarding potential lean body mass loss affecting performance.

  • Open Access

    EFFICACY AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN THE TREATMENT OF ANDROGENETIC ALOPECIA – A LITERATURE REVIEW

    by Filip Kieloch, Agnieszka Fitas, Karol Kanon, Mathias Spitaleri, Wiktor Gąska, Oskar Sienkiel, Julia Głowacka, Wojciech Gąska, Dawid Sewruk, Karolina Dębek-Kalinowska

    Introduction: Androgenetic alopecia (AGA) is a chronic progressive form of hair loss affecting a significant portion of the adult population. Although topical minoxidil has a proven efficacy, it is often associated with low adherence due to adverse effects and the inconvenience of use. Increasing attention is being paid to low-dose oral minoxidil (LDOM), which may represent a therapeutic alternative with a favorable safety profile. Purpose of The Work: The aim of this study was to assess the efficacy and safety of low-dose oral minoxidil (≤5 mg/day) in the treatment of androgenetic alopecia based on current clinical trial data. Material and Methods: A narrative literature review was conducted, including studies published in English between 2019 and 2024, concerning the efficacy and safety in patients with AGA. A total of 9 publications meeting the inclusion criteria were analyzed. Results: The analyzed studies demonstrated that LDOM increases both the number and diameter of hair in patients – in both men and women. The best results were observed at doses of 1-5 mg/day, although even very low doses (0.25 mg/day) yielded measurable effects. Adverse events were generally mild – most commonly hypertrichosis and cardiovascular symptoms (e.g., tachycardia), with incidence increasing with dose. Serious complications were rare and occurred primarily in patients with pre-existing heart disease. Conclusion: Low-dose oral minoxidil is an effective and well-tolerated treatment option for AGA. Further studies are needed to standarize dosing and assess the long-term safety of the therapy.